REGN Stock Recent News
REGN LATEST HEADLINES
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California , won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition $250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET Company Participants Ryan Crowe - SVP, IR & Strategic Analysis Chris Fenimore - CFO Conference Call Participants David Risinger - Leerink Partners David Risinger All right. So we're going to get started.
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135096&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline.
LOS ANGELES--(BUSINESS WIRE)--REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135082&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135049&wire=1 or contact Joseph E. Levi, Esq.